Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and X-Chem, leader in DNA-encoded library (DEL) ...
HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $11 t...
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges ...
REFINED BUSINESS OUTLOOK FOR FULL-YEAR 2024
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and prog...
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress furth...
